Clinical Trial Update: Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating ASC41 for nonalcoholic steatohepatitis (NASH) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• ASC41

Snippet

Sponsor: Gannex Pharma Co., Ltd. | Conditions: Nonalcoholic Steatohepatitis (NASH) | Phase 2 | Status: WITHDRAWN